EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Development and validation of a nomogram based on pretreatment dynamic contrast-enhanced MRI for the prediction of pathologic response after neoadjuvant chemotherapy for triple-negative breast cancer

Yanbo Li, Yongzi Chen, Rui Zhao, Yu Ji, Junnan Li, Ying Zhang, Hong Lu

European Radiology · 2022-03 · 32 (3) · 1676-1687

DOI: 10.1007/s00330-021-08291-0 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Radiology, online erschienen am 12.11.2021. Verfasst von Yanbo Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Imaging, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, People…. Hauptthemen laut MEDLINE: Breast Neoplasms, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Research projects for pharmacy, laboratory science, and radiology, Tianjin Medical University Cancer Institute and Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: To develop a nomogram based on pretreatment dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to predict pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) in patients with triple-negative breast cancer (TNBC). METHODS: A total of 108 female patients with TNBC treated with neoadjuvant chemotherapy followed by surgery between January 2017 and October 2020 were enrolled. The patients were randomly divided into the primary cohort (n = 87) and validation cohort (n = 21) at a ratio of 4:1. The pretreatment DCE-MRI and clinicopathological features were reviewed and recorded. Univariate analysis and multivariate logistic regression analyses were used to determine the independent predictors of pCR in the primary cohort. A nomogram was developed based on the predictors, and the predictive performance of the nomogram was evaluated by the area under the receiver operating characteristic (ROC) curve (AUC). The validation cohort was used to test the predictive model. RESULTS: Tumor volume measured on DCE-MRI, time to peak (TTP), and androgen receptor (AR) status were identified as independent predictors of pCR. The AUCs of the nomogram were 0.84 (95% CI: 0.75-0.93) and 0.79 (95% CI: 0.59-0.99) in the primary cohort and validation cohort, respectively. CONCLUSIONS: Pretreatment DCE-MRI could predict pCR after NAC in patients with TNBC. The nomogram can be used to predict the probability of pCR and may help individualize treatment. KEY POINTS: • Pretreatment DCE-MRI findings can predict pathologic complete response (pCR) after neoadjuvant chemotherapy in patients with triple-negative breast cancer. • A nomogram based on the independent predictors of tumor volume measured on DCE-MRI, time to peak, and androgen receptor status could help personalized cancer treatment in TNBC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsTriple Negative Breast NeoplasmsFemaleHumansMagnetic Resonance ImagingNeoadjuvant TherapyNomogramsRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

Magnetic resonance imagingNeoadjuvant chemotherapyNomogramTriple negative breast cancer

Autor:innen und Institutionen

  • Department of Breast Imaging, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, People's Republic of China.
  • Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Tianjin, People's Republic of China.
  • Laboratory of Tumor Cell Biology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, People's Republic of China.
  • Department of Breast Imaging, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, People's Republic of China. honglu@tmu.edu.cn.
  • Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Tianjin, People's Republic of China. ho…

Förderung

  • Research projects for pharmacy, laboratory science, and radiology, Tianjin Medical University Cancer Institute and Hospital

Zitieren

APA

Li, Y., Chen, Y., Zhao, R., Ji, Y., Li, J., Zhang, Y., & Lu, H. (2022). Development and validation of a nomogram based on pretreatment dynamic contrast-enhanced MRI for the prediction of pathologic response after neoadjuvant chemotherapy for triple-negative breast cancer. European Radiology, 32(3), 1676-1687. https://doi.org/10.1007/s00330-021-08291-0

Vancouver

Li Y, Chen Y, Zhao R, Ji Y, Li J, Zhang Y, et al. Development and validation of a nomogram based on pretreatment dynamic contrast-enhanced MRI for the prediction of pathologic response after neoadjuvant chemotherapy for triple-negative breast cancer. European Radiology. 2022;32(3):1676-1687. doi:10.1007/s00330-021-08291-0

BibTeX
@article{Li2022,
  author = {Li, Yanbo and Chen, Yongzi and Zhao, Rui and Ji, Yu and Li, Junnan and Zhang, Ying and Lu, Hong},
  title = {Development and validation of a nomogram based on pretreatment dynamic contrast-enhanced MRI for the prediction of pathologic response after neoadjuvant chemotherapy for triple-negative breast cancer},
  journal = {European Radiology},
  year = {2022},
  volume = {32},
  number = {3},
  pages = {1676--1687},
  doi = {10.1007/s00330-021-08291-0}
}
Kostenlos starten →